Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors

被引:19
作者
Gupta, SP [1 ]
Babu, MS [1 ]
Garg, R [1 ]
Sowmya, S [1 ]
机构
[1] Birla Inst Technol & Sci, Pilani 333031, Rajasthan, India
来源
JOURNAL OF ENZYME INHIBITION | 1998年 / 13卷 / 06期
关键词
quantitative structure-activity relationship; HIV-1 protease inhibitors; cyclic urea derivatives; QSAR;
D O I
10.3109/14756369809020545
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A quantitative structure-activity relationship (QSAR) study is described on some cyclic ureas that inhibit the enzyme HIV-I protease (HIV-1-PR) and exhibit antiviral potency. Both the enzyme inhibition activity and the antiviral potency were found to be primarily governed by the hydrophobic property of the substituents at the nitrogens (N2/N2') of the urea. Adjacent to the nitrogens, the C1/C1'-substituents are, however, found to affect the activity (inhibition) by their molecular size. The essential binding of the ureas with the receptor is, however, through multiple hydrogen bonding, where the substituents, too, can participate in such binding if they are capable of doing so. A schematic diagram of the overall interaction of the inhibitors with the receptor is presented.
引用
收藏
页码:399 / 407
页数:9
相关论文
共 16 条
[1]  
Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654
[2]  
Boehme RE, 1995, ANNU REP MED CHEM, V30, P139
[3]   Quantitative structure-activity relationship studies on some anti-human-immunodeficiency-virus-1 (anti-HIV-1) drugs: Viral reverse transcriptase inhibitors [J].
Garg, R ;
Gupta, SP .
JOURNAL OF ENZYME INHIBITION, 1997, 12 (01) :1-12
[4]   Quantitative structure-activity relationship studies on some acyclouridine derivatives acting as anti-HIV-1 drugs [J].
Garg, R ;
Kurup, A ;
Gupta, SP .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1997, 16 (01) :20-24
[5]   Quantitative structure-activity relationship studies on some viral reverse transcriptase inhibitors acting as anti-HIV-1 agents [J].
Garg, R ;
Gupta, SP .
JOURNAL OF ENZYME INHIBITION, 1997, 11 (03) :171-181
[6]   Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase [J].
Gupta, SP ;
Garg, R .
JOURNAL OF ENZYME INHIBITION, 1996, 11 (01) :23-32
[7]   CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MUTANTS WITH DECREASED SENSITIVITY TO PROTEINASE-INHIBITOR RO-31-8959 [J].
JACOBSEN, H ;
YASARGIL, K ;
WINSLOW, DL ;
CRAIG, JC ;
KROHN, A ;
DUNCAN, IB ;
MOUS, J .
VIROLOGY, 1995, 206 (01) :527-534
[8]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[9]   Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas [J].
Lam, PYS ;
Ru, Y ;
Jadhav, PK ;
Aldrich, PE ;
DeLucca, GV ;
Eyermann, CJ ;
Chang, CH ;
Emmett, G ;
Holler, ER ;
Daneker, WF ;
Li, LZ ;
Confalone, PN ;
McHugh, RJ ;
Han, Q ;
Li, RH ;
Markwalder, JA ;
Seitz, SP ;
Sharpe, TR ;
Bacheler, LT ;
Rayner, MM ;
Klabe, RM ;
Shum, LY ;
Winslow, DL ;
Kornhauser, DM ;
Jackson, DA ;
EricksonViitanen, S ;
Hodge, CN .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (18) :3514-3525
[10]   RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS [J].
LAM, PYS ;
JADHAV, PK ;
EYERMANN, CJ ;
HODGE, CN ;
RU, Y ;
BACHELER, LT ;
MEEK, JL ;
OTTO, MJ ;
RAYNER, MM ;
WONG, YN ;
CHANG, CH ;
WEBER, PC ;
JACKSON, DA ;
SHARPE, TR ;
ERICKSONVIITANEN, S .
SCIENCE, 1994, 263 (5145) :380-384